Hypha Labs (FUNI) 10-Q 14 Feb 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Dec. 31, 2023	Feb. 14, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	Digipath, Inc.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6450 Cameron St
Entity Address, Address Line Two	Suite 113
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		87,096,820

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash	$ 308,252	$ 271,006
Note receivable, net of allowance of $625,000
Other current assets	8,090	8,570
Assets held for sale - current	556,023	486,222
Total current assets	872,365	765,798
Assets held for sale – long term	648,498	643,666
Total non-current assets	648,498	643,666
Total Assets	1,520,863	1,409,464
Current liabilities:
Accounts payable	92,220	122,094
Current maturities of notes payable	595,965	565,000
Liabilities held for sale - current	308,532	368,655
Total current liabilities	3,089,234	3,121,814
Non-current liabilities:
Liabilities held for sale – long term	150,336	159,156
Total non-current liabilities	150,336	159,156
Total Liabilities	3,239,570	3,280,970
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 shares issued and outstanding as of December 31, 2023 and September 30, 2023	333,600	333,600
Commitments and Contingencies
Stockholders’ Deficit:
Common stock, $0.001 par value, 250,000,000 shares authorized; 87,096,820 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively	87,097	87,097
Additional paid-in capital	17,469,899	17,468,746
Accumulated deficit	(19,610,351)	(19,761,997)
Total Stockholders’ Deficit	(2,052,307)	(2,205,106)
Total Liabilities and Stockholders’ Deficit	1,520,863	1,409,464
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value	1,048	1,048
Series C Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value
Nonrelated Party [Member]
Current liabilities:
Accrued expenses – related party	320,235	328,491
Current maturities of convertible notes payable related parties, net of discounts	1,407,945	1,385,932
Related Party [Member]
Current liabilities:
Accrued expenses – related party	17,760	12,390
Current maturities of convertible notes payable related parties, net of discounts	$ 346,577	$ 339,252

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Allowance for note receivable	$ 625,000	$ 625,000
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	87,096,820	87,096,820
Common stock, shares outstanding	87,096,820	87,096,820
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series C Convertible Preferred Stock [Member]
Temporary equity, shares issued	0
Temporary equity, shares outstanding	0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues
Cost of sales
Gross profit
Operating expenses:
General and administrative	14,743	39,524
Professional fees	55,821	67,812
Total operating expenses	70,564	107,336
Operating loss	(70,564)	(107,336)
Other income (expense):
Other Expense		(55,000)
Other income	13,896
Interest expense	(84,313)	(97,152)
Total other expense	(70,417)	(152,152)
Net loss from continuing operations	(140,981)	(259,488)
Net income from discontinued operations	292,627	19,158
Net income (loss)	$ 151,646	$ (240,330)
Weighted average number of common shares outstanding – basic	87,096,820	82,219,103
Weighted average number of common shares outstanding – fully diluted	87,096,820	82,219,103
Net loss per share from continuing operations – basic	$ 0	$ 0
Net income per share from discontinued operations – basic	0	0
Net income (loss) per share – basic	0	0
Net loss per share from continuing operations – diluted	0	0
Net income per share from discontinued operations – diluted	0	0
Net income (loss) per share – diluted	$ 0	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Stock Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Total
Balance at Sep. 30, 2022	$ 333,600	$ 1,048	$ 1	$ 75,147	$ 71,745	$ 17,117,958	$ (20,008,771)			$ (2,742,872)
Balance, shares at Sep. 30, 2022	333,600
Balance at Sep. 30, 2022	$ 333,600
Balance, shares at Sep. 30, 2022		1,047,942	1,000	75,146,820
Stock-based compensation						8,306				8,306
Net income (loss)							(240,330)			(240,330)
Issuance of common shares to settle stock payable				$ 7,150	(71,745)	64,595
Issuance of common shares to settle stock payable, shares				7,150,000
Warrants issued as debt financing costs						93,938				93,938
Balance at Dec. 31, 2022	$ 333,600	$ 1,048	$ 1	$ 82,297		17,284,797	(20,249,101)			(2,880,958)
Balance, shares at Dec. 31, 2022	333,600
Balance at Dec. 31, 2022	$ 333,600
Balance, shares at Dec. 31, 2022		1,047,942	1,000	82,296,820
Balance at Sep. 30, 2023	$ 333,600	$ 1,048		$ 87,097		17,468,746	(19,761,997)			(2,205,106)
Balance, shares at Sep. 30, 2023	333,600							333,600
Balance at Sep. 30, 2023	$ 333,600									333,600
Balance, shares at Sep. 30, 2023		1,047,942		87,096,820
Stock-based compensation						1,153				1,153
Net income (loss)							151,646			151,646
Balance at Dec. 31, 2023	$ 333,600	$ 1,048		$ 87,097		$ 17,469,899	$ (19,610,351)			(2,052,307)
Balance, shares at Dec. 31, 2023	333,600							333,600	0
Balance at Dec. 31, 2023	$ 333,600									$ 333,600
Balance, shares at Dec. 31, 2023		1,047,942		87,096,820

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss from continuing operations	$ (140,981)	$ (259,488)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,153	8,306
Amortization of debt discounts	29,338	48,916
Impairment of fixed assets		55,000
Decrease (increase) in assets:
Other current assets	480	4,904
Increase (decrease) in liabilities:
Accounts payable	(24,082)	33,087
Accrued expenses	17,286	(34,508)
Accrued expenses – related parties	5,000	12,000
Net cash used in operating activities from continuing operations	(111,806)	(131,784)
Net cash provided by operating activities from discontinued operations	176,503	149,017
Net cash provided by operating activities	64,697	17,233
Cash flows from investing activities
Proceeds from sale of collateralized assets		100,000
Net cash provided by (used in) investing activities from continuing operations		100,000
Net cash used in investing activities from discontinued operations	(11,667)	(2,666)
Net cash provided by (used in) investing activities	(11,667)	97,334
Cash flows from financing activities
Net cash used in financing activities from continuing operations
Net cash used in financing activities from discontinued operations	(15,784)	(14,904)
Net cash used in financing activities	(15,784)	(14,904)
Net increase (decrease) in cash	37,246	99,664
Cash – beginning	271,006	56,168
Cash – ending	308,252	155,832
Supplemental disclosures:
Interest paid	40,018	26,166
Income taxes paid
Non-cash investing and financing activities:
Common stock issued for settlement of stock payable		71,745
Warrants issued for debt financing		93,938
Receipt of assets on deposit		6,076
Accounts payable and accrued interest added to note principal balance	$ 30,965

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	3 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc (1) Nevada Parent Digipath Labs, Inc Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S (3) Colombia Subsidiary VSSL Enterprises, Ltd (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc. (“Digipath Labs”), which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests , For the three months ended December 31, 2023 and 2022, all revenues are classified as part of Net income from discontinued operations Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of December 31, 2023 and September 30, 2023. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the periods ended December 31, 2023 and 2022. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the periods ended December 31, 2023 and 2022. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the three months ended December 31, 2023 and 2022, potential dilutive securities of 83,125,488 8,120,000 6,020,000 15,387,050 13,579,710 our Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	3 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, as 2,216,869 19,610,351 308,252 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2023 and September 30, 2023, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 308,252 $ - $ - Liabilities Notes payable - 595,965 - Convertible notes payable, net of discounts of $ 13,713 - - 1,754,522 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 271,006 $ - $ - Liabilities Notes payable - 565,000 - Convertible notes payable, net of discounts of $ 43,051 - - 1,725,184 There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended December 31, 2023.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions During the three months ended December 31, 2023 the Company incurred compensation expense of $ 15,000 During the three months ended December 31, 2023 the Company accrued fees of $ 5,000 15,000 As of December 31, 2023, the Company has accrued a total of $ 2,760

Note Receivable

Note Receivable	3 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Note Receivable	Note 5 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On various dates between August 23, 2021 and September 30, 2022, we loaned C3 Labs, Inc. (“C3 Labs”) a total of $ 1,056,570 8 had August 23, 2022 64,017 The loans were made in connection with a potential acquisition of a controlling interest in C3 Labs pursuant to a letter of intent. On March 11, 2022, the Company notified the current owners of C3 Labs of its termination of the letter of intent and took possession of the equipment of C3 Labs (“C3 Equipment”). On December 8, 2022, the Company entered into an Asset Purchase Agreement with Invictus Wealth Group (“Invictus”), whereby the Company agreed to sell the C3 Equipment to Invictus for a total purchase price of $ 900,000 275,000 note receivable 625,000 December 31, 2023 10 100,000 425,000 275,000 100,000 425,000 50,000 100,000 125,000 216,780 The Company recorded a full allowance against the Invictus Note, as of the transaction date, as collectability was not reasonably assured at of the transaction date.

Notes Payable

Notes Payable	3 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Notes Payable	Note 6 – Notes Payable Notes payable consists of the following at December 31, 2023 and September 30, 2023, respectively: Schedule of Notes Payable December 31, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 100,000 125,000 Canna Lab Canna Lab 35,965 Canna Lab Note $ 595,965 $ 565,000 Total notes payable 595,965 565,000 Less: current maturities (595,965 ) (565,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 18,026 12,000 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 79,548 80,428

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7 – Convertible Notes Payable Related party convertible Schedule of Related Party Convertible Notes Payable December 31, September 30, 2023 2023 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 matured August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 , 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party $ 350,000 $ 350,000 Total related party convertible notes payable 350,000 350,000 Less: unamortized debt discounts (3,423 ) (10,748 ) Total convertible debt 346,577 339,252 Less: current maturities (346,577 ) (339,252 ) Related party convertible notes payable $ - $ - Convertible notes payable consist of the following at December 31, 2023 and September 30, 2023, respectively: Schedule of Convertible Notes Payable December 31, September 30, 2023 2023 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 matured August 11, 2022 , as amended 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 matured August 11, 2022 , as amended 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 , 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 matured August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 , 355,469 98,188 February 11, 2024 4,621,105 32,166 , 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 matured August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 , 350,000 350,000 On October 1, 2022, the 8 February 11, 2024 362,765 0.01 4,715,945 30,102 , 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 matured August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,234 1,418,234 Less: unamortized debt discounts (10,289 ) (32,302 ) Total convertible debt 1,407,945 1,385,932 Less: current maturities (1,407,945 ) (1,385,932 ) Convertible notes payable $ - $ - In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $ 93,938 , 2023 29,338 48,916 13,712 All of the convertible notes (except the related party convertible note) 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 37,527 36,236 The Company recognized interest expense for the three months ended December 31, 2023 and 2022, respectively, as follows: Schedule of Interest Expense December 31, December 31, 2023 2022 Interest on notes payable 18,026 12,000 Amortization of beneficial conversion features 29,338 48,916 Interest on convertible notes 36,949 36,236 Total interest expense $ 84,313 $ 97,152

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stockholders’ Equity	Note 8 – Stockholders’ Equity Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 1,500,000 1,000 2,499,000 1,047,942 333,600 no the Series A The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 5,239,710 No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred , voting separately as a class, ● Pursuant to various Series C The shares of and each share has a Stated Value of $ 1 each the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock 0.10 Additional terms of the Series C Preferred include the following: ● The shares of Series C Preferred are not entitled to dividends. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series C Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the stated value per share of Series C Preferred. ● The shares of Series C Preferred have no Common Stock The Company has 250,000,000 of common stock, par value $ 0.001 87,096,820

Mezzanine Equity

Mezzanine Equity	3 Months Ended
	Dec. 31, 2023
Mezzanine Equity
Mezzanine Equity	Note 9 – Mezzanine Equity Series B The shares of 1.00 0.04 333,600 8,340,000 No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice Additional terms of the Series B Preferred include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number of into ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such shares of Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet.

Common Stock Options

Common Stock Options	3 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 10 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012, and terminated on March 5, 2022. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 Amortization of Stock-Based Compensation A total of $ 1,153 8,306 no The following is a summary of information about the stock options outstanding at December 31, 2023. Summary of Common Stock Options Outstanding Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 4.78 $ 0.052 8,120,000 $ 0.052 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 8,120,000 $ 0.052 Options issued - - Options forfeited - - Balance, December 31, 2023 8,120,000 $ 0.052 Exercisable, December 31, 2023 8,120,000 $ 0.052 As of December 31, 2023, these options in the aggregate had $ 88,740 0.04

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Dec. 31, 2023
Common Stock Warrants
Common Stock Warrants	Note 11 – Common Stock Warrants Warrants to purchase a total of 15,387,050 The following is a summary of information about our warrants to purchase common stock outstanding at December 31, 2023 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 8.21 $ 0.016 15,387,050 $ 0.016 The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 15,387,050 $ 0.016 Warrants granted - - Warrants expired - - Balance, December 31, 2023 15,387,050 $ 0.016 Exercisable, December 31, 2023 15,387,050 $ 0.016 As of December 31, 2023, these warrants in the aggregate had $ 630,198 0.04

Discontinued Operations

Discontinued Operations	3 Months Ended
	Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 12 – Discontinued Operations On April 20, 2023, the Company 2,300,000 150,000 The Purchase Agreement includes a number of representations, warrantees, covenants and conditions to closing customary for this type of transaction. In addition, the closing of the transaction is subject to the approval of the Nevada Cannabis Compliance Board (the “CCB”). Subsequent to December 31, 2023, the Company received approval from the CCB. See Note 14 Pursuant to the Purchase Agreement, the Buyer deposited $ 230,000 In connection with the transactions contemplated by the Purchase Agreement, Digipath, Digipath Labs and Buyer entered into a Management Services Agreement (the “Management Services Agreement”), dated as of April 30, 2023, pursuant to which Buyer was engaged to manage the operation of Digipath Labs’ cannabis testing laboratory (the “Lab”). The effectiveness of the Management Services Agreement was subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $ 15,000 The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures December 31, 2023 September 30, 2023 Current assets: Accounts receivable, net $ 509,535 $ 447,410 Deposits 18,675 18,675 Other current assets 27,813 20,137 Total current assets 556,023 486,222 Right-of-use asset 274,985 274,985 Fixed assets, net 373,513 368,681 Total long term assets 648,498 643,666 Total Assets $ 1,204,521 $ 1,129,888 Current liabilities: Accounts payable $ 132,669 $ 158,869 Accrued expenses 60,358 61,512 Current portion of operating lease liabilities 66,772 83,757 Current maturities of notes payable 48,733 64,517 Total current liabilities 308,532 368,655 Operating lease liabilities 134,425 143,245 Notes payable 15,911 15,911 Total long term liabilities 150,336 159,156 Total Liabilities $ 458,868 $ 527,811 The statements of operations of Digipath Labs combined are summarized below: 2023 2022 For the Three Months Ended December 31, 2023 2022 Revenues $ 923,154 $ 726,755 Cost of sales 421,511 422,835 Gross profit 501,643 303,920 Operating expenses: General and administrative 203,185 280,644 Professional fees 4,750 2,157 Total operating expenses 207,935 282,801 Operating income 293,708 21,119 Other income (expense): Interest expense (1,081 ) (1,961 ) Total other income (expense) (1,081 ) (1,961 ) Net income $ 292,627 $ 19,158

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events On January 3, 2024 , December 31, 2025 50,000 100,000 125,000 216,780 On January 18, 2024, the Company received approval from the CCB to transfer the assets pursuant to the Purchase Agreement. The Company expects the transaction to close by the end of February 2024.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Nature of Business	Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc (1) Nevada Parent Digipath Labs, Inc Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S (3) Colombia Subsidiary VSSL Enterprises, Ltd (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc. (“Digipath Labs”), which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests , For the three months ended December 31, 2023 and 2022, all revenues are classified as part of Net income from discontinued operations
Discontinued Operations	Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of December 31, 2023 and September 30, 2023. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the periods ended December 31, 2023 and 2022. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the periods ended December 31, 2023 and 2022. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the three months ended December 31, 2023 and 2022, potential dilutive securities of 83,125,488 8,120,000 6,020,000 15,387,050 13,579,710 our
Reclassifications	Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc (1) Nevada Parent Digipath Labs, Inc Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S (3) Colombia Subsidiary VSSL Enterprises, Ltd (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2023 and September 30, 2023, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 308,252 $ - $ - Liabilities Notes payable - 595,965 - Convertible notes payable, net of discounts of $ 13,713 - - 1,754,522 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 271,006 $ - $ - Liabilities Notes payable - 565,000 - Convertible notes payable, net of discounts of $ 43,051 - - 1,725,184

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at December 31, 2023 and September 30, 2023, respectively: Schedule of Notes Payable December 31, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 100,000 125,000 Canna Lab Canna Lab 35,965 Canna Lab Note $ 595,965 $ 565,000 Total notes payable 595,965 565,000 Less: current maturities (595,965 ) (565,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 18,026 12,000 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 79,548 80,428

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Related Party Convertible Notes Payable	Related party convertible Schedule of Related Party Convertible Notes Payable December 31, September 30, 2023 2023 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 matured August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 , 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party $ 350,000 $ 350,000 Total related party convertible notes payable 350,000 350,000 Less: unamortized debt discounts (3,423 ) (10,748 ) Total convertible debt 346,577 339,252 Less: current maturities (346,577 ) (339,252 ) Related party convertible notes payable $ - $ -
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at December 31, 2023 and September 30, 2023, respectively: Schedule of Convertible Notes Payable December 31, September 30, 2023 2023 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 matured August 11, 2022 , as amended 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 matured August 11, 2022 , as amended 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 , 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 matured August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 , 355,469 98,188 February 11, 2024 4,621,105 32,166 , 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 matured August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 , 350,000 350,000 On October 1, 2022, the 8 February 11, 2024 362,765 0.01 4,715,945 30,102 , 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 matured August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,234 1,418,234 Less: unamortized debt discounts (10,289 ) (32,302 ) Total convertible debt 1,407,945 1,385,932 Less: current maturities (1,407,945 ) (1,385,932 ) Convertible notes payable $ - $ -
Schedule of Interest Expense	The Company recognized interest expense for the three months ended December 31, 2023 and 2022, respectively, as follows: Schedule of Interest Expense December 31, December 31, 2023 2022 Interest on notes payable 18,026 12,000 Amortization of beneficial conversion features 29,338 48,916 Interest on convertible notes 36,949 36,236 Total interest expense $ 84,313 $ 97,152

Common Stock Options (Tables)

Common Stock Options (Tables)	3 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at December 31, 2023. Summary of Common Stock Options Outstanding Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 4.78 $ 0.052 8,120,000 $ 0.052
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 8,120,000 $ 0.052 Options issued - - Options forfeited - - Balance, December 31, 2023 8,120,000 $ 0.052 Exercisable, December 31, 2023 8,120,000 $ 0.052

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Dec. 31, 2023
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at December 31, 2023 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 8.21 $ 0.016 15,387,050 $ 0.016
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 15,387,050 $ 0.016 Warrants granted - - Warrants expired - - Balance, December 31, 2023 15,387,050 $ 0.016 Exercisable, December 31, 2023 15,387,050 $ 0.016

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures	The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures December 31, 2023 September 30, 2023 Current assets: Accounts receivable, net $ 509,535 $ 447,410 Deposits 18,675 18,675 Other current assets 27,813 20,137 Total current assets 556,023 486,222 Right-of-use asset 274,985 274,985 Fixed assets, net 373,513 368,681 Total long term assets 648,498 643,666 Total Assets $ 1,204,521 $ 1,129,888 Current liabilities: Accounts payable $ 132,669 $ 158,869 Accrued expenses 60,358 61,512 Current portion of operating lease liabilities 66,772 83,757 Current maturities of notes payable 48,733 64,517 Total current liabilities 308,532 368,655 Operating lease liabilities 134,425 143,245 Notes payable 15,911 15,911 Total long term liabilities 150,336 159,156 Total Liabilities $ 458,868 $ 527,811 The statements of operations of Digipath Labs combined are summarized below: 2023 2022 For the Three Months Ended December 31, 2023 2022 Revenues $ 923,154 $ 726,755 Cost of sales 421,511 422,835 Gross profit 501,643 303,920 Operating expenses: General and administrative 203,185 280,644 Professional fees 4,750 2,157 Total operating expenses 207,935 282,801 Operating income 293,708 21,119 Other income (expense): Interest expense (1,081 ) (1,961 ) Total other income (expense) (1,081 ) (1,961 ) Net income $ 292,627 $ 19,158

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	3 Months Ended
	Dec. 31, 2023
Entities Under Common Control and Ownership One [Member]
Name of Entity	Digipath, Inc	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs CA, Inc	[2]
Jurisdiction of Incorporation	California
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S	[3]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd	[4]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
[1]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.[2]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations.[3]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.[4]Acquired on March 11, 2020.

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended
	Apr. 20, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Cash purchase price			$ 100,000
Conversion of preferred shares		8,340,000
Series A Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of preferred shares		13,579,710	13,579,710
Convertible Debt Securities [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		83,125,488	83,125,488
Share-Based Payment Arrangement, Option [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		8,120,000	6,020,000
Warrant [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		15,387,050	15,387,050
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Cash purchase price	$ 2,300,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working Capital	$ 2,216,869
Accumulated deficit	19,610,351	$ 19,761,997
Cash	$ 308,252	$ 271,006

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	$ 308,252	$ 271,006
Notes payable
Convertible notes payable, net of discounts of $43,051
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash
Notes payable	595,965	565,000
Convertible notes payable, net of discounts of $43,051
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash
Notes payable
Convertible notes payable, net of discounts of $43,051	$ 1,754,522	$ 1,725,184

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Convertible Debt [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 13,713	$ 43,051

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	3 Months Ended
	Dec. 31, 2023 USD ($)
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Service for incurred fees	$ 15,000
Board Of Directors [Member]
Related Party Transaction [Line Items]
Service for incurred fees	5,000
Due to related party	15,000
Officer And Directors [Member]
Related Party Transaction [Line Items]
Reimbursable expenses	$ 2,760

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)

13 Months Ended

Dec. 31, 2025

Sep. 30, 2025

Sep. 30, 2025

Jun. 30, 2025

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Sep. 30, 2024

Sep. 30, 2024

Jun. 30, 2024

Jun. 30, 2024

Mar. 31, 2024

Dec. 31, 2023

Sep. 30, 2023

Jun. 30, 2023

Dec. 08, 2022

Sep. 30, 2022

Jun. 13, 2019

Financing Receivable, Modified [Line Items]

Purchase price note receivable

Extended Maturity [Member] | Forecast [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 216,780

$ 125,000

$ 100,000

$ 100,000

$ 50,000

$ 50,000

$ 50,000

Northwest Analytical Labs, Inc. [Member]

Financing Receivable, Modified [Line Items]

Notes receivable

$ 95,000

Debt instrument stated percentage

10%

C3 Labs, Inc., [Member]

Financing Receivable, Modified [Line Items]

Notes receivable

$ 1,056,570

Debt instrument stated percentage

8%

Debt instrument maturity date

Aug. 23, 2022

Interest receivable

$ 64,017

Invictus Wealth Group [Member] | Asset Purchase Agreement [Member]

Financing Receivable, Modified [Line Items]

Debt instrument stated percentage

10%

Debt instrument maturity date

Dec. 31, 2023

Purchase price note receivable

$ 900,000

Upfront payment

275,000

Purchase price note receivable

$ 625,000

Debt final payment

425,000

$ 100,000

Received portion of upfront payment

$ 275,000

Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Extended Maturity [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 100,000

Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Extended Maturity [Member] | Forecast [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 216,780

$ 125,000

$ 100,000

$ 100,000

$ 50,000

$ 50,000

$ 50,000

$ 425,000

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Short-Term Debt [Line Items]
Total notes payable	$ 595,965	$ 565,000
Less: current maturities	(595,965)	(565,000)
Notes payable
Notes Payable [Member]
Short-Term Debt [Line Items]
Total notes payable	595,965	565,000
Notes Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Total notes payable	$ 79,548	$ 80,428

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)			3 Months Ended	12 Months Ended
	Sep. 10, 2021	Dec. 26, 2019	Dec. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Canna Lab Note [Member]
Short-Term Debt [Line Items]
Additional debt amount	$ 675,000
Debt instrument stated percentage	12%
Debt instrument, maturity date	Sep. 10, 2024
Debt instrument periodic payment	$ 22,419.66
Secured Promissory Note [Member]
Short-Term Debt [Line Items]
Additional debt amount					$ 115,000
Repayments of notes payable				$ 100,000	$ 125,000
Accrued interest			$ 35,965
Note Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Debt instrument stated percentage		5.75%
Debt instrument, maturity date		Dec. 26, 2024
Debt instrument periodic payment		$ 5,622
Payments for lab equipment		377,124
Proceeds from bank loan		$ 291,931
Debt instrument term description		5 years

Schedule of Related Party Conve

Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 1,418,234	$ 1,418,234
Total convertible debt	1,407,945	1,385,932
Less: current maturities	(1,407,945)	(1,385,932)
Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable	350,000	350,000
Less: unamortized debt discounts	(3,423)	(10,748)
Total convertible debt	346,577	339,252
Less: current maturities	(346,577)	(339,252)
Related party convertible notes payable
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Less: unamortized debt discounts	(13,712)
Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 350,000	$ 350,000

Schedule of Related Party Con_2

Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) - Secured Subordinated Convertible Promissory Note [Member] - Accredited Investors [Member] - USD ($)	Aug. 08, 2022	Dec. 29, 2020	Dec. 28, 2020	Feb. 11, 2020
Short-Term Debt [Line Items]
Principal amount		$ 50,000	$ 400,000	$ 350,000
Maturity date	Feb. 11, 2024			Aug. 10, 2022
Debt instrument interest percentage				9%
Conversion price		$ 0.03	$ 0.03	$ 0.15
Proceeds from convertible debt			$ 50,000
Debt converted principal value, shares		1,666,667
Shares of common stock issued	4,550,000
Debt instrument fair value	$ 43,788
Debt instrument agreement	As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,418,234	$ 1,418,234
Less: unamortized debt discounts	(10,289)	(32,302)
Total convertible debt	1,407,945	1,385,932
Less: current maturities	(1,407,945)	(1,385,932)
Nonrelated Party [Member]
Short-Term Debt [Line Items]
Convertible notes payable
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	355,469	355,469
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	362,765	362,765
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	$ 150,000	$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

3 Months Ended

12 Months Ended

Oct. 02, 2022

Aug. 08, 2022

Sep. 30, 2021

Feb. 22, 2021

Dec. 29, 2020

Dec. 28, 2020

Sep. 30, 2020

Feb. 11, 2020

Sep. 23, 2019

Nov. 08, 2018

Nov. 05, 2018

Dec. 31, 2023

Dec. 31, 2022

Sep. 30, 2022

Short-Term Debt [Line Items]

Amortization of debt discount premium

$ 29,338

$ 48,916

Debt instrument purchase of warrant

15,387,050

9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 10,000

$ 60,000

$ 50,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 10,000

Debt converted principal value, shares

333,334

Shares issued in exchange of extension

650,000

Debt instrument fair value

$ 6,989

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 200,000

$ 150,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 50,000

Debt converted principal value, shares

1,666,667

Debt converted principal amount

$ 50,000

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors One [Member]

Short-Term Debt [Line Items]

Shares issued in exchange of extension

1,950,000

Debt instrument fair value

$ 20,968

Senior Secured Convertible Note [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.03

$ 0.11

Proceeds from convertible debt

$ 200,000

Debt converted principal value, shares

3,000,000

Debt converted principal amount

$ 90,000

Debt instrument periodic payment

$ 355,469

Amortization of debt discount premium

$ 98,188

Debt instrument purchase of warrant

4,621,105

Debt instrument fair value of warrant

$ 32,166

Senior Secured Convertible Note One [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 350,000

Debt instrument purchase of warrant

4,550,000

Debt instrument fair value of warrant

$ 31,671

Senior Secured Convertible Note Two [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Debt instrument interest percentage

8%

Conversion price

$ 0.01

Debt instrument purchase of warrant

4,715,945

Debt instrument fair value of warrant

$ 30,102

Debt conversion original debt amount

$ 362,765

Senior Secured Convertible Note Three [Member]

Short-Term Debt [Line Items]

Maturity date

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 150,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Note Payable [Member]
Short-Term Debt [Line Items]
Interest expense	$ 18,026	$ 12,000

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Interest on notes payable	$ 18,026	$ 12,000
Amortization of beneficial conversion features	29,338	48,916
Interest on convertible notes	36,949	36,236
Total interest expense	$ 84,313	$ 97,152

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2023
Short-Term Debt [Line Items]
Amortization of debt discounts	$ 29,338	$ 48,916
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt discount conversion feature of convertible debt			$ 93,938
Amortization of debt discounts	$ 29,338	48,916
Unamortized discounts	13,712
Convertible notes interest expense	$ 37,527	$ 36,236

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - $ / shares	3 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jul. 20, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized	10,000,000
Preferred stock, par or stated value per share	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	87,096,820	87,096,820
Common stock, shares outstanding	87,096,820	87,096,820
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000
Preferred stock, par or stated value per share			$ 1
Preferred stock, shares designated remaining	2,499,000
Preferred stock voting rights	the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock
Preferred stock voting rights	$ 0.10
Conversion of stock description	Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series C Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the stated value per share of Series C Preferred.
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000	1,000
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Temporary equity, shares issued	0
Temporary equity, shares outstanding	0
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted	1,047,942
Convertible shares	5,239,710
Common stock, terms of conversion	No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice
Percentage of distribution on purchase price	100%
Series A Preferred Stock [Member] | Noteholders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership	4.99%

Mezzanine Equity (Details Narra

Mezzanine Equity (Details Narrative)	3 Months Ended
	Dec. 31, 2023 $ / shares shares
Preferred stock, par value	$ 0.001
Conversion of stock shares issued | shares	8,340,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 1
Conversion price	$ 0.04
Conversion shares converted | shares	333,600
Common stock, terms of conversion	No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice
Conversion of stock description	Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	3 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.0056
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	8,120,000
Weighted Average Remaining Contractual Life	4 years 9 months 10 days
Weighted Average Exercise Price	$ 0.052
Number of Shares Exercisable | shares	8,120,000
Weighted Average Exercise Price Exercisable	$ 0.052

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details)	3 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning balance	8,120,000
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 0.052
Number of Shares Options issued
Weighted Average Exercise Price, Options issued | $ / shares
Number of Shares Options forfeited
Weighted Average Exercise Price, Options issued
Number of Shares Outstanding, Ending balance	8,120,000
Weighted Average Exercise Price, Outstanding, Ending | $ / shares	$ 0.052
Number of Shares Exercisable, Ending	8,120,000
Weighted Average Exercise Price, Exercisable, Ending | $ / shares	$ 0.052

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		3 Months Ended
	Jun. 21, 2016	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Intrinsic value , outstanding		$ 88,740
Market price, per share		$ 0.04
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses		$ 1,153	$ 8,306
Unamortized expenses expected to be expensed		$ 0
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	3 Months Ended
	Dec. 31, 2023 $ / shares shares
Common Stock Warrants
Exercise Price Range Lower Range	$ 0.0074
Exercise Price Range Upper Range	$ 0.10
Number of Warrants Outstanding | shares	15,387,050
Weighted Average Remaining Contractual Life	8 years 2 months 15 days
Weighted Average Exercise Price	$ 0.016
Number of Warrants Exercisable | shares	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details)	3 Months Ended
	Dec. 31, 2023 $ / shares shares
Common Stock Warrants
Number of Shares, Balance beginning | shares	15,387,050
Weighted Average Exercise Price, Balance beginning	$ 0.016
Number of Shares, Warrants granted | shares
Weighted Average Exercise Price, Warrants granted
Number of Shares, Warrants expired | shares
Weighted Average Exercise Price, Warrants expired
Number of Shares, Balance ending | shares	15,387,050
Weighted Average Exercise Price, Balance, ending	$ 0.016
Weighted Average Exercise Price, Balance, ending	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	3 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Number of warrant to purchase of common stock shares | shares	15,387,050
Warrant [Member]
Warrants, intrinic value | $	$ 630,198
Intrinsic value, market price per share | $ / shares	$ 0.04

Schedule of Discontinued Operat

Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2023
Current assets:
Accounts receivable, net	$ 509,535		$ 447,410
Deposits	18,675		18,675
Other current assets	27,813		20,137
Total current assets	556,023		486,222
Right-of-use asset	274,985		274,985
Fixed assets, net	373,513		368,681
Total long term assets	648,498		643,666
Total Assets	1,204,521		1,129,888
Current liabilities:
Accounts payable	132,669		158,869
Accrued expenses	60,358		61,512
Current portion of operating lease liabilities	66,772		83,757
Current maturities of notes payable	48,733		64,517
Total current liabilities	308,532		368,655
Operating lease liabilities	134,425		143,245
Notes payable	15,911		15,911
Total long term liabilities	150,336		159,156
Total Liabilities	458,868		$ 527,811
Revenues	923,154	$ 726,755
Cost of sales	421,511	422,835
Gross profit	501,643	303,920
Operating expenses:
General and administrative	203,185	280,644
Professional fees	4,750	2,157
Total operating expenses	207,935	282,801
Operating income	293,708	21,119
Other income (expense):
Interest expense	(1,081)	(1,961)
Total other income (expense)	(1,081)	(1,961)
Net income	$ 292,627	$ 19,158

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)			3 Months Ended
	Apr. 30, 2023	Apr. 20, 2023	Dec. 31, 2023	Dec. 31, 2022	Apr. 20, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price				$ 100,000
Working capital			$ (2,216,869)
Escrow deposits					$ 230,000
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Working capital		$ 150,000
Management Services Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Description of collaborative arrangement	The effectiveness of the Management Services Agreement was subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $15,000) in each month, Buyer was entitled to a management fee of $10,000 per month. Any remaining cash generated from the operation of the Lab in any month was payable 45% to the Buyer and 55% to the Company.
Payment of cash collections	$ 15,000
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price		$ 2,300,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 31, 2025	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Jan. 03, 2024
Forecast [Member] | Extended Maturity [Member]
Subsequent Event [Line Items]
Debt final payment	$ 216,780	$ 125,000	$ 100,000	$ 100,000	$ 50,000	$ 50,000	$ 50,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument, maturity date								Dec. 31, 2025